Secondary hypertension is a main clinical issue and molecular underlying mechanism need deep investigation to unravel novel paths for interventional protocols. The equilibrium among steroid compounds is major pathway with high potential for novel prospectives. The present study highlights for the first time that 11 Beta-Hydroxysteroid Dehydrogenase Type 2 Promoter Polymorphisms Determines a Decreased HSD11B2 Expression in Vivo
11 Beta-Hydroxysteroid Dehydrogenase Type2 Promoter Polymorphisms Determines a Decreased HSD11B2 Expression in Vivo
FRISO, Simonetta;OLIVIERI, Oliviero;
2014-01-01
Abstract
Secondary hypertension is a main clinical issue and molecular underlying mechanism need deep investigation to unravel novel paths for interventional protocols. The equilibrium among steroid compounds is major pathway with high potential for novel prospectives. The present study highlights for the first time that 11 Beta-Hydroxysteroid Dehydrogenase Type 2 Promoter Polymorphisms Determines a Decreased HSD11B2 Expression in Vivo
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
